Streszczenie
W części I pracy scharakteryzowano najczęściej występujące działania niepożądane leków w środowisku jamy ustnej, omówiono mechanizm wydzielania śliny oraz przedstawiono skutki uboczne leków moczopędnych (diuretyków) w jamie ustnej. W części II przedstawiono działania niepożądane pozostałych grup leków hipotensyjnych w jamie ustnej – β‑blokerów, blokerów kanałów wapniowych oraz inhibitorów konwertazy angiotensyny.

Abstract
In part I of the study the most common side effects of oral medications were described and the mechanism of salivation and the side effects of diuretics in the oral cavity were discussed. Part II of the study outlines the side effects of other groups of oral antihypertensive drugs – β‑blockers, calcium channel blockers and angiotensin converting enzyme inhibitors.

Hasła indeksowe: nadciśnienie tętnicze, leki hipotensyjne, jama ustna, ślina

Key words: hypertension, antihypertensive drugs, oral cavity, diuretics

PIŚMIENNICTWO

1. Tykarski A. i wsp.: Zasady postępowania w nadciśnieniu tętniczym — 2015 rok, Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Via Medica, 2015.
2. Tamargo J., Segura J., Ruilope L.M.: Diuretics in the treatment of hypertension. Part 2: Loop diuretics and potassium-sparing agents. Expert Opin. Pharmacother., 2014, 15, 605-621.
3. Garnock-Jones K.P.: Irbesartan/Amlodipine : a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. Am. J. Cardiovasc. Drugs, 2013, 13, 2, 141-150.
4. Maciejczyk M., Rysiak E., Car H.: Działania niepożądane produktów leczniczych w praktyce klinicznej – aspekt kliniczny i ekonomiczny. Pol. Przegl. Nauk Zdr., 2016, 4, 5-8.
5. Lo Russo L. i wsp.: Adverse drug reactions in the oral cavity. Curr. Pharm. Design., 2012, 18, 5481-5496.
6. Seymour R.A., Rudralingham M.: Oral and dental adverse drug reactions. Periodontol. 2000, 2008, 46, 9-26.
7. Pejcic A.: Emerging trends in oral health sciences and dentistry. Drug-induced oral reactions. Intech, 2015, DOI: 10.5772/59267.
8. Mason R.P., Giles T.D., Sowers J.R.: Evolving mechanisms of action of beta blockers: focus on nebivolol. J. Cardiovasc. Pharmacol., 2009, 54, 2, 123-128.
9. Gorre F., Vandekerckhove H.: Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol., 2010, 65, 565-570.
10. Chung J.F., Lee S.J., Sood A.K.: Immunological and pleiotropic effects of individual β-blockers and their relevance in cancer therapies in cancer therapies. Expert Opin. Inv. Drug., 2016, DOI: 10.1517/13543784.2016.1164141
11. Kalinowski L., Dobrucki W., Szczepańska-Konkel M .i wsp.: Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux. Circulation, 2003, 107, 2747-2752.
12. de Matos L.F. i wsp.: Relationships of beta-blockers and anxiolytics intake and salivary secretion, masticatory performance and taste perception. Arch. Oral Biol., 2010, 55, 164-169.
13. Pereira L.J. i wsp.: Oral physiology, nutrition and quality of life in diabetic patients associated or not with hypertension and beta-blockers therapy. J. Oral Rehabil., 2016, 43, 511-518.
14. Streckfus C.F., Welsh S., Strahl R.C.: Diminution of parotid IgA secretion in an elderly black population taking antihypertension medications. Oral Surg. Oral Med. Oral Pathol., 1991, 71, 50-54.
15. Dehpour A.R. i wsp.: On the relation of calcium channel blockers to rat parotid and submandibular glands function in vivo. Gen. Pharmac., 1995, 23, 619-622.
16. Levine M., Curry S.C., Padilla-Jones A., Ruha A.M.: Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann. Emerg. Med., 2013, 62, 3, 252-258.
17. Maier H., Antonczyk G., Schindler J.G., Heidland A.: Effect of verapamil on ionized calcium excretion in human parotid saliva. Eur. J. Clin. Pharmacol., 1979, 16, 7-9.
18. Mnguni A.T., Engel M.E., Borkum M.S., Mayosi B.M: The Effects of angiotensin converting enzyme inhibitors (ACE-I) on human N-levels : a systematic review and meta-analysis. PLoS One, 2015, 10, 1-10.
19. Regulski M., Regulska K., Stanisz B.J. i wsp.: Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr. Pharm. Des., 2015, 21. 1764-1775.
20. Nederfors T. i wsp.: Effects of the antihypertensive drug captopril on human salivary secretion rate and composition. Eur. J. Oral Sci.,1995,103, 351-354.
21. Djukić L.J. i wsp.: The effects of antihypertensives and type 2 diabetes on salivary flow and total antioxidant capacity. Oral Dis., 2015, 21, 5, 619-625.
22. Mahmoudpour S.H. i wsp.: Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacoqenomics, 2013, 14, 249-260.
23. Nonzee V., Manopatanakul S.: Xerostomia, hyposalivation and oral microbiota in patients using antihypertensive medications. J. Med. Assoc. Thai., 2012, 95, 96-104.
24. Raebel M.A.: Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther., 2012, 30, 156-166.
25. Leto L., Aspromonte N., Feola M.: Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev., 2014, 19, 237-246.
26. Yuan A., Woo S.: Adverse drug events in the oral cavity. Oral Med., 2015, 119, 35-47.
27. Maciejczyk M. i wsp.: Polekowe zaburzenia wydzielania śliny. Mag. Stomatol., 2015, 25, 5, 123-126.
28. Nederfors T., Nauntofte B., Twetman S.: Effects of furosemide and bendroflumethiazide on saliva flow rate and composition. Arch. Oral Biol., 2004, 49, 507-513.
29. Liu Y.F. i wsp.: Burning mouth syndrome: a systematic review of treatments. Oral Dis., 2017, DOI: 10.1111/odi.12660.
30. Briggs E.R.: Taste disturbances related to medication use. Consult. Pharm., 2009, 24, 7, 538-543.